A recent
report published by Infinium Global Research on the peptide therapeutics market
provides in-depth analysis of segments and sub-segments in the global as well
as regional peptide therapeutics market. The study also highlights the impact
of drivers, restraints, and macro indicators on the global and regional peptide
therapeutics market over the short term as well as long term. The report is a
comprehensive presentation of trends, forecast and dollar values of the global
peptide therapeutics market. According to the report, the global peptide
therapeutics market is projected to grow at a CAGR of 10% over the forecast
period of 2022-2028. The revenue generated by the market was USD approximately
37 billion in 2021 and is expected to reach approximately USD 64 billion in
2028.
Market
Insight
The peptide
therapeutics market is projected to register a 10% CAGR during the forecast
period. Peptides are short chains of amino acids linked by a peptide bond; they
perform many roles within the cell including signaling and anti-infective. The
suitability of the peptide for therapeutic use depends on the sequence, whether
it is based on those peptides that are naturally produced by the body, similar to
those naturally produced, or a sequence novel to the body. The key factors
driving the market growth are the increasing prevalence of cancer and metabolic
disorders, rising investments in research and development of novel drugs, and
technological advancements in peptide therapeutics. According to the World
Health Organization (WHO), chronic diseases, such as cancer, cardiovascular
diseases, and diabetes, are the leading causes of death and disability
worldwide. Furthermore, the consistently increasing cancer populations across
the globe with technological advancements are likely to uncover growth
opportunities throughout the forecasted period.
Peptides are
being made and repurposed as therapeutics for the treatment of covid-19.
Researchers are still searching for the compounds that will either stop the
replication process of SARS-CoV-2 or treat conditions caused by the infection,
worldwide. On February 21, 2020, the FDA updated its definition of a biologic
to include chemically synthesized polypeptides greater than 40 amino acids but
less than 100 amino acids in size (synthetic proteins) and synthetic peptides
40 amino acids or less. As of May 2020, there were 21 peptide drugs for the
treatment of COVID-19, including 15 synthetic peptides in development for the
treatment of acute respiratory distress syndrome (ARDS) and other respiratory
illnesses caused by SARS-Cov-2 infection. Therefore, in the conclusion,
COVID-19 may have a positive impact on the peptide therapeutics market as
peptide drugs are being considered as a treatment option for dealing with
COVID-19. Nevertheless, the current applications of peptide therapeutics in
oncology, metabolic disorders, etc., have been disrupted due to a shortage of
drugs and supply chain issues, along with the slow progress of clinical trials
related to non-COVID-19 therapeutics.
Infinium Global Research's recent report on the “Peptides therapeutics
market" offers an ample outline of the factors responsible for the growth
of the market. This Peptides therapeutics market report includes all the
details such as all the new recent developments, import-export analysis,
production analysis, strategic market growth product launches, and much other
information.
The global
peptide therapeutics market has experienced progressive growth over the past
few years. Growth in the global market is highly credible to the rising
prevalence of metabolic disorders coupled with an increasing pool of cancer
patients. Moreover, recent technological advancements have reduced the production
cost of peptide drugs thereby fuelling growth remarkably in the global market.
Rising research activities and the development pipeline of peptide drugs are
anticipated to provide numerous growth opportunities over the forecast period.
Although driven by the aforementioned factors, growth in this market is
hampered by the complexity of peptide therapies may limit the manufacturing of
peptide drugs. Furthermore, the consistently increasing cancer population
across the globe with technological advancements is likely to uncover growth
opportunities throughout the forecasted period. Additionally, the increasing
incidence of metabolic disorders across the globe will also be expected to
create numerous growth opportunities in the forthcoming years.
The report
provides a regional outlook covering geographies such as North America, Europe,
Asia-Pacific, and the Rest of the World. North America holds the command over
the global peptide therapeutics market and is expected to dominate the overall
market during the forecast period. The market growth is due to factors such as
a rise in awareness levels relating to peptide therapeutic products, the
increasing necessity for diagnostics in cancer and other diseases, and the
growing biotechnology industry. The region is anticipated to retain its
dominance throughout the forecasted period driven by advanced healthcare
infrastructure in this region. Moreover, the presence of established players in
this region contributed significantly to the regional growth. Following North
America, Europe stands second in the global market including major markets such
as Germany, Spain, Netherland, and the UK. The emergence of pharmaceutical and
biotech companies, massive investment in healthcare startups, and rising
initiatives from government authorities to develop cost-effective and safe
drugs are some of the important market drivers in this region. On the other
hand, Asia Pacific anticipated emerging as the most lucrative region by growing
at the highest CAGR in the years to come. This is due sophisticated healthcare
infrastructure in this region as well as the growing cancer population along
with increasing incidences of metabolic disorders.
Segment
Covered
The report
on the global peptide therapeutics market covers segments such as marketing type,
application, and route of administration. On the basis of marketing type, the
sub-markets include generic and branded. On the basis of application, the
sub-markets include gastrointestinal disorders, neurological disorders,
metabolic disorders, cancer, and other applications. On the basis of route of
administration, the sub-markets include parenteral, oral, and other routes of
administration.
Companies
Profiled:
The report
provides profiles of the companies in the market such as Teva Pharmaceutical
Industries Ltd., Takeda Pharmaceutical Co. Ltd., Sanofi SA, Pfizer Inc,
Novartis AG, GlaxoSmithKline Plc, Hoffmann-La Roche Ltd., Eli Lilly, and Co.,
Bachem Holding AG, and Amgen Inc.
Report
Highlights:
The report
provides deep insights into the demand forecasts, market trends, and micro and
macro indicators. In addition, this report provides insights into the factors
that are driving and restraining the growth in this market. Moreover, The
IGR-Growth Matrix analysis given in the report brings an insight into the
investment areas that existing or new market players can consider. The report
provides insights into the market using analytical tools such as Porter's five
forces analysis and DRO analysis of the peptide therapeutics market. Moreover, the
study highlights current market trends and provides forecast from 2022-2028. We
also have highlighted future trends in the market that will affect the demand
during the forecast period. Moreover, the competitive analysis given in each
regional market brings an insight into the market share of the leading players.